Life Sciences Tools and Services
Company Overview of Hadasit Medical Research Services & Development Ltd.
Hadasit Medical Research Services & Development Ltd., a technology transfer company, identifies, protects, nurtures, and commercializes inventions developed in Hadassah. The company assists physicians and researchers in defining the medical unmet needs, aligning the inventions and supporting research with regulatory and market expectations, and raising funds to support proof-of-concept development. It also offers pre-clinical services, including cell biology clinical diagnostics, consultations and counseling, disease models and experimental surgery, drug discovery, genetics, GMP production, imaging, neurology, pharmacology, vaccines and immunotherapy, and virology and immunology. In addition...
Hadassah Ein Kerem
Founded in 1986
Key Executives for Hadasit Medical Research Services & Development Ltd.
Vice President of Finance & Contracts
Compensation as of Fiscal Year 2017.
Hadasit Medical Research Services & Development Ltd. Key Developments
Kadimastem Selects Hadasit Medical Research Services & Development Ltd. to Perform the Clinical Trial on its Cell Therapy Product for the Treatment of ALS
Nov 2 16
Kadimastem announced that it has signed a letter of intent with Hadasit Medical Research Services & Development Ltd. for the performance of the clinical trial on Kadimastem's cell therapy product for the treatment of ALS.
BiolineRx Signs In-Licensing Deal for Liver Fibrosis Treatment with Hadasit
Aug 1 16
BioLineRx has signed an exclusive worldwide agreement with Hadasit, for the in-licensing of drug candidate BL-1210 to treat liver fibrosis. It is the first project to be in-licensed under the framework of the company's strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.
Immune Pharmaceuticals Inc. and Hadasit Files Provisional Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies
Jun 7 16
Immune Pharmaceuticals Inc. and Hadasit announced that they together filed a provisional patent on the oral use of anti-eotaxin monoclonal antibodies, including Immune's bertilimumab, for the treatment of inflammatory gastro-intestinal (GI) and liver diseases. Immune signed a licensing agreement with Hadasit in conjunction with the provisional patent filing. Immune is currently conducting a double blind placebo controlled phase IIA clinical trial in Ulcerative Colitis, with parenteral bertilimumab. Immune is currently collaborating with Professor Arun Sanyal, former President of the American Liver Association, and Professor of Medicine at Virginia Commonwealth University (VCU) Medical Center to obtain additional insights on the potential role of eotaxin in NASH. Phase II clinical trials in patients with NASH are planned to follow these collaborative studies. Eotaxin-1, a specific chemokine, plays a role in both innate and adaptive immune responses and modulates the cross-talk between key cells involved in inflammation. Bertilimumab is a first-in-class monoclonal antibody that blocks eotaxin-1, is designed for personalized therapy in inflammatory conditions mediated by high eotaxin-1 levels, among which are Crohn's Disease and Ulcerative Colitis, NASH, and primary sclerosing cholangitis (PSC). Alleviation of insulin resistance is also associated with decreased eotaxin-1.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|